Venus Remedies get marketing nod for six Chemotherapy Drugs

Venus Remedies, a global oncology drug provider, has received marketing approval for six crucial chemotherapy drugs in the Philippines, marking a significant stride in the ASEAN region. These approvals include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, solidifying Venus Remedies' position in the dynamic $420 billion pharmaceutical market of the Philippines. With this achievement, Venus Remedies now holds 525 marketing approvals for its oncology products across 76 countries.

Saransh Chaudhary, CEO of Venus Medicine Research Centre, emphasized the company's goal of becoming the premier oncology medicine supplier from India in Southeast Asia. The Philippines' market for cancer drugs, which is projected to grow at a CAGR of 8.7% by 2025, provides immense opportunities for Venus Remedies to expand its operations in the Asia-Pacific region.

Additionally, Venus Remedies' oncology wing has received marketing authorization for the chemotherapy drug oxaliplatin in Myanmar, furthering the company's footprint in the ASEAN region. These achievements underscore Venus Remedies' commitment to delivering advanced cancer therapies globally.